$2.49 EPS Expected for Celgene Co. (CELG) This Quarter

Brokerages expect that Celgene Co. (NASDAQ:CELG) will post $2.49 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Six analysts have made estimates for Celgene’s earnings, with the lowest EPS estimate coming in at $2.34 and the highest estimate coming in at $2.80. Celgene reported earnings of $2.05 per share during the same quarter last year, which suggests a positive year-over-year growth rate of 21.5%. The firm is scheduled to issue its next quarterly earnings report on Friday, May 3rd.

According to Zacks, analysts expect that Celgene will report full year earnings of $10.71 per share for the current fiscal year, with EPS estimates ranging from $10.43 to $11.20. For the next fiscal year, analysts forecast that the business will post earnings of $12.77 per share, with EPS estimates ranging from $12.32 to $13.20. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Celgene.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.32 by $0.07. Celgene had a return on equity of 114.66% and a net margin of 26.48%. The company had revenue of $4.04 billion for the quarter, compared to analyst estimates of $3.98 billion. During the same period last year, the company earned $2.00 earnings per share.

Several equities analysts have weighed in on the company. Zacks Investment Research lowered Celgene from a “buy” rating to a “hold” rating in a report on Wednesday, April 3rd. ValuEngine upgraded Celgene from a “sell” rating to a “hold” rating in a report on Saturday, March 30th. Mizuho set a $103.00 target price on Celgene and gave the company a “buy” rating in a report on Friday, April 5th. UBS Group lowered Celgene from a “buy” rating to a “neutral” rating and raised their target price for the company from $94.00 to $102.00 in a report on Monday, April 1st. Finally, Atlantic Securities lowered Celgene from an “overweight” rating to a “neutral” rating and set a $94.34 target price on the stock. in a report on Monday, April 1st. One research analyst has rated the stock with a sell rating, eighteen have given a hold rating and nine have given a buy rating to the stock. Celgene currently has a consensus rating of “Hold” and a consensus target price of $99.41.

In other Celgene news, Director Ernest Mario purchased 2,000 shares of the stock in a transaction dated Tuesday, February 12th. The shares were bought at an average cost of $89.99 per share, with a total value of $179,980.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James J. Loughlin sold 23,466 shares of the firm’s stock in a transaction dated Thursday, February 7th. The shares were sold at an average price of $87.29, for a total value of $2,048,347.14. Following the completion of the sale, the director now directly owns 62,102 shares in the company, valued at $5,420,883.58. The disclosure for this sale can be found here. Company insiders own 0.39% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Bruderman Asset Management LLC acquired a new stake in Celgene during the fourth quarter worth about $25,000. Murphy Pohlad Asset Management LLC acquired a new stake in Celgene during the fourth quarter worth about $25,000. Athena Capital Advisors LLC acquired a new stake in Celgene during the fourth quarter worth about $27,000. Liberty Wealth Management LLC acquired a new stake in Celgene during the fourth quarter worth about $29,000. Finally, Berman Capital Advisors LLC acquired a new stake in Celgene during the fourth quarter worth about $32,000. 74.81% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ CELG opened at $93.76 on Friday. Celgene has a fifty-two week low of $58.59 and a fifty-two week high of $95.44. The company has a debt-to-equity ratio of 3.21, a quick ratio of 2.12 and a current ratio of 2.23. The stock has a market cap of $65.86 billion, a price-to-earnings ratio of 12.32, a P/E/G ratio of 0.43 and a beta of 1.71.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: Why is total return important?

Get a free copy of the Zacks research report on Celgene (CELG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.